A New Indication for Finerenone, a Mineralocorticoid-Receptor Antagonist

The FDA has approved this drug for treating patients with heart failure and preserved or mildly reduced ejection fraction.

On July 14, 2025, the U.S. FDA approved use of finerenone (Kerendia) “to reduce the risk of … cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction ≥40%.”

Background

Finerenone is a nonsteroidal mineralocorticoid-receptor antagonist; it was approved in 2021 for patients with type 2 diabetes and chronic kidney disease after studies showed that it lowered the incidence of adverse renal and cardiovascular outcomes in those patients. However, its efficacy in patients with heart failure and preserved (or mildly reduced) ejection fraction had not been established.

The study that led to the additional approved indication

Approval for this ne…

Authors

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

A New Indication for Finerenone, a Mineralocorticoid-Receptor Antagonist

Topics

Background

The study that led to the additional approved indication

Authors